286 358

Cited 0 times in

Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab

 Choong-Kun Lee  ;  Seung-Seob Kim  ;  Saemi Park  ;  Chan Kim  ;  Su Jin Heo  ;  Joon Seok Lim  ;  Hyunki Kim  ;  Hyo Song Kim  ;  Sun Young Rha  ;  Hyun Cheol Chung  ;  Sohee Park  ;  Minkyu Jung 
 ONCOTARGET , Vol.8(19) : 31169-31179, 2017 
Journal Title
Issue Date
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Agents, Immunological/therapeutic use* ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers, Tumor ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Staging ; Prognosis ; ROC Curve ; Stomach Neoplasms/diagnosis* ; Stomach Neoplasms/drug therapy* ; Stomach Neoplasms/mortality ; Trastuzumab/administration & dosage ; Trastuzumab/adverse effects ; Trastuzumab/therapeutic use* ; Treatment Outcome
depth of response ; early tumor shrinkage ; gastric cancer ; survival ; trastuzumab
PURPOSE: We aimed to determine and compare the predictive values of depth of response (DpR) and early tumor shrinkage (ETS) on long-term outcomes in gastric cancer patients treated with trastuzumab. RESULTS: From a total of 368 computed tomography examinations, DpR and ETS were evaluated. DpR was a significant tumor-size metric in predicting PFS and OS, and showed better discriminatory ability (higher Cτ indices, 0.6957 for PFS; 0.7191 for OS) than ETS. DpR ≥ 45% (vs. < 45%) was the optimal cutoff value, as it was best able to identify patients with longer PFS (median 9.0 vs. 6.3 months, hazard ratio [HR] = 0.608; 95% confidence interval [CI]: 0.335 to 1.104; P = 0.102) and OS (median 23.5 vs. 13.1 months, HR = 0.441; 95% CI: 0.203 to 0.955; P = 0.038). MATERIALS AND METHODS: Sixty-one gastric cancer patients who received first-line trastuzumab-based chemotherapy were assessed for DpR and ETS. We employed Kaplan-Meier estimates, log-rank tests, Cox proportional hazards regression models, time-dependent receiver operating characteristics, and Youden's J index to evaluate and determine cutoff values of DpR and ETS as predictors of progression-free survival (PFS) and overall survival (OS). CONCLUSIONS: DpR and ETS were significant predictors of long-term outcomes in gastric cancer patients treated with first-line trastuzumab. Validation in prospective trials with larger patient populations is needed.
Files in This Item:
T201701509.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers
4. Graduate School of Public Health (보건대학원) > Graduate School of Public Health (보건대학원) > 1. Journal Papers
Yonsei Authors
Kim, Seung-seob(김승섭) ORCID logo https://orcid.org/0000-0001-6071-306X
Kim, Hyunki(김현기) ORCID logo https://orcid.org/0000-0003-2292-5584
Kim, Hyo Song(김효송) ORCID logo https://orcid.org/0000-0002-0625-9828
Rha, Sun Young(라선영) ORCID logo https://orcid.org/0000-0002-2512-4531
Park, So Hee(박소희) ORCID logo https://orcid.org/0000-0001-8513-5163
Lee, Choong-kun(이충근) ORCID logo https://orcid.org/0000-0001-5151-5096
Lim, Joon Seok(임준석) ORCID logo https://orcid.org/0000-0002-0334-5042
Jung, Min Kyu(정민규) ORCID logo https://orcid.org/0000-0001-8281-3387
Chung, Hyun Cheol(정현철) ORCID logo https://orcid.org/0000-0002-0920-9471
Heo, Su Jin(허수진) ORCID logo https://orcid.org/0000-0002-0615-5869
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.